Development of multivalent CAR T cells as dual immunotherapy and conditioning agents

Development of multivalent CAR T cells as dual immunotherapy and conditioning agents

Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for pediatric acute myeloid leukemia (AML). Despite adjustments in HSCT protocols and improvements in supportive care, 30% of high-risk patients who receive HSCT as part of their therapy still experience disease relapse with...

Full description

Bibliographic Details
Main Authors: Quenton Rashawn Bubb, Mohammad Balood, Gabe Eduardo Seir, Leah Swartzrock, Ethan Haslett, Katie Ho, Peng Xu, Saida G. Wiltz, Elena Sotillo, Tanja A. Gruber, Rebecca M. Richards, Crystal L. Mackall, Agnieszka Czechowicz
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
CAR-T
AML
pediatric AML
HSCT
trispecific
Online Access:http://www.sciencedirect.com/science/article/pii/S295032992500013X

Internet

http://www.sciencedirect.com/science/article/pii/S295032992500013X

Similar Items